BridgeBio Pharma, Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of BBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending September 30, 2022 was 9227.22% (a 18582.36% increase compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue increased by 2071.77%
  • Annual Selling, General and Administrative Expense of Revenue for 2021 was 275.7% (a -84.05% decrease from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2020 was 1728.65% (a 643.09% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 232.63% (a Infinity% increase from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending September 30, 2022 was 187.31% (a -6.15% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue decreased by -32.06% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
187.31% 199.59% 268.53% 275.7%
Visit stockrow.com/BBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of BridgeBio Pharma, Inc.

Most recent Selling, General and Administrative Expense of Revenueof BBIO including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 9227.22% 49.39% 2580.46%
2021 424.87% 1966.04% 85.09% 9828.35% 275.7%
2020 30686.07% 443.16% 0.0% 0.0% 1728.65%
2019 253.07% 87.86% 0.0% 0.0% 232.63%
2018 0.0% 0.0%
2017 0.0%

Business Profile of BridgeBio Pharma, Inc.

Sector: Healthcare
Industry: Biotechnology